Tag: Tuberculous meningitis

According to pharmacokinetic modeling, rifampicin concentrations in cerebrospinal fluid (CSF) can be significantly lower than plasma levels with standard administration, prompting the critical question: **Does rifampicin penetrate the brain?**. This limited access is a major challenge for treating severe central nervous system (CNS) infections.

Tuberculous meningitis (TB meningitis) is a devastating infection with high mortality and neurological disability rates, partly because standard doses of rifampin exhibit poor penetration across the blood-brain barrier (BBB), leading to subtherapeutic concentrations in the central nervous system (CNS).